GlassScriptPhysician profile
Lindsey Robins
NPI 1609491018
$1,575.38
in general payments reported to CMS, 2019-2025
19 companies · $571 in 2025
The $571 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $60.90 · 2023: $279 · 2024: $492 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $221.06 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $187.31 | 2024-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $152.86 | 2024-2025 | Nemluvio |
| Vyne Pharmaceuticals INC. | $125.00 | 2021 | |
| Janssen Biotech, INC. | $121.87 | 2025 | Tremfya |
| Incyte Corporation | $106.99 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $100.87 | 2022-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $85.18 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $74.40 | 2023-2025 | Ilumya |
| Pfizer INC. | $65.76 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $61.54 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $56.44 | 2023 | Farxiga |
| Dermavant Sciences, INC. | $52.52 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $40.67 | 2023-2024 | Zoryve |
| Lilly USA, LLC | $30.19 | 2025 | Taltz, Ebglyss |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $24.92 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.75 | 2024 | Cabtreo |
| Sandoz INC. | $22.12 | 2024 | Hyrimoz |
| Journey Medical Corporation | $21.93 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Robins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.